Health
Biotechnology
Pharmaceutical

Vertex Pharmaceuticals

$181.53
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$1.03 (-0.56%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell VRTX and other stocks, options, ETFs, and crypto commission-free!

About

Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. Read More The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Employees
2,500
Headquarters
Boston, Massachusetts
Founded
1989
Market Cap
46.58B
Price-Earnings Ratio
22.46
Dividend Yield
0.00
Average Volume
1.44M
High Today
$183.85
Low Today
$181.06
Open Price
$182.07
Volume
651.97K
52 Week High
$195.81
52 Week Low
$144.07

Collections

Health
Biotechnology
Pharmaceutical
Manufacturing
Cancer Prevention
Therapy
Technology
US

News

MarketWatchMar 19

Vertex Pharmaceuticals Inc.

Vertex Pharmaceuticals Inc. announced Wednesday afternoon that Chief Operating Officer and interim Chief Financial Officer Ian Smith had been terminated as "the result of personal behavior that violated Vertex's Code of Conduct and values." Vertex said that the decision was made after an investigation that included the help of outside counsel, but did not specify Smith's actions. "At Vertex, we are deeply committed to our culture of diversity, inclusion and respect, and we insist that all of our employees, ...

253
TradingNewsNowMar 19

Latest Technicals: Vertex Pharmaceuticals (NASDAQ: VRTX)

Vertex Pharmaceuticals is in the healthcare sector and trades as part of the biotechnology industry. The company CEO is Jeffrey M Leiden. Vertex Pharmaceuticals Inc is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases in specialty markets. Its products include SYMDEKO, ORKAMBI, and KALYDECO. Previous Intraday Trading Performance: The VRTX stock showed a previous change of -0.32% with an open at 188.00 and a close o...

55
Yahoo FinanceMar 13

CELG vs. VRTX: Which Stock Is the Better Value Option?

PepsiCo (PEP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Celgene (CELG) or Vertex Pharmaceuticals (VRTX). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank wi...

66

Earnings

$0.30
$0.63
$0.97
$1.30
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected Apr 24, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.